Abstract
This review deals with the applications of 67Gallium (Ga) scintigraphy for the initial staging and follow-up during and after treatment of patients with Hodgkin's or non-Hodgkin's lymphoma (NHL). During the last decade, the technique of visualization has been largely improved by using higher doses and additional tomography. Here, the indications for 67Ga scintigraphy in comparison with CT and MRI are discussed. The conditions resulting in false positive and false negative results have been outlined. 67Ga may detect unusual involved sites during staging procedures. However, the major contribution to the management of Hodgkin's disease and NHL is the evaluation of residual masses, because 67Ga uptake reflects the metabolic activity of the tumor. The review ends with an additional short overview of other radionuclide imaging methods useful for malignant lymphoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
